Codagenix's IND application for CodaVax-RSV receives US FDA approval.

M2 EQUITYBITES-June 2, 2022-Codagenix's IND application for CodaVax-RSV receives US FDA approval

(C)2022 M2 COMMUNICATIONS http://www.m2.com

Codagenix Inc., a US-based clinical-stage synthetic biology company, announced on Wednesday that it has received approval from the US Food and Drug Administration (FDA) for the Investigational New Drug (IND) application for CodaVax-RSV, an intranasal, live-attenuated vaccine candidate, intended to prevent respiratory syncytial virus (RSV) infection in healthy infants and toddlers.

With the approval, the firm is also planning to start a phase one study of vaccine safety and immunogenicity against RSV in healthy children aged six months to five years. This is based on a phase one study of CodaVax-RSV in adults 55-75 years old that achieved its primary safety endpoint and indicated strong anti-RSV-specific cellular immune responses.

J Robert Coleman, co-founder and chief executive officer of Codagenix, said...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT